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Abstract
Background: The standard way to stop smoking is to stop abruptly on a quit day with no prior
reduction in consumption of cigarettes. Many smokers feel that reduction is natural and if reduction
programmes were offered, many more might take up treatment. Few trials of reduction versus
abrupt cessation have been completed. Most are small, do not use pharmacotherapy, and do not
meet the standards necessary to obtain a marketing authorisation for a pharmacotherapy.
Design/Methods: We will conduct a non-inferiority randomised trial of rapid reduction versus
standard abrupt cessation among smokers who want to stop smoking. In the reduction arm,
participants will be advised to reduce smoking consumption by half in the first week and to 25% of
baseline in the second, leading up to a quit day at which participants will stop smoking completely.
This will be assisted by nicotine patches and an acute form of nicotine replacement therapy. In the
abrupt arm participants will use nicotine patches only, whilst smoking as normal, for two weeks
prior to a quit day, at which they will also stop smoking completely. Smokers in either arm will have
standard withdrawal orientated behavioural support programme with a combination of nicotine
patches and acute nicotine replacement therapy post-cessation.
Outcomes/Follow-up: The primary outcome of interest will be prolonged abstinence from
smoking, with secondary trial outcomes of point prevalence, urges to smoke and withdrawal
symptoms. Follow up will take place at 4 weeks, 8 weeks and 6 months post-quit day.
Trial Registration: Current Controlled Trials ISRCTN22526020
Background
Without help, most smokers who try to stop smoking
relapse within one week and only 4% of quit attempts sus-
tain abstinence for one year[1]. The best treatment results
in about 22% one year prolonged abstinence[2], and the
UK National Health Service (NHS) specialist stop smok-
ing services achieve around 15% one year abstinence[3].
NHS support in primary care achieves around 7% one
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improves substantially the number who achieve absti-
nence, whatever method of stopping is used, return to
smoking is the norm for the majority and, even with treat-
ment, the majority of relapsers resume smoking during
active treatment. Thus we have a cadre of patients who
have been through treatment services many times. Cur-
rently, the NHS gives the same treatment on repeated
attempts to stop as on the first attempt. Patients often
choose different pharmacotherapies, but in other respects,
the treatment is the same every time. A common sense
view is that offering repeated courses of identical treat-
ment that failed previously might be less effective than try-
ing different treatment. Rapid reduction might offer a new
way to quit to those who have failed previously.
The standard assumption of all smoking cessation treat-
ment is that cessation begins on a quit day and cutting
down prior to quitting is not advised. This is because of
the belief that with reduction each remaining cigarette
will become more rewarding and harder to give up and in
the meantime the smoker will suffer a loss of motivation
before reaching the point where total abstinence is
attained.
Smokers, however, feel that cutting down is an appropri-
ate way to stop smoking. In the English Smoking Toolkit
Study, 57% of current smokers reported they were cutting
down, of whom 26% were using nicotine replacement
therapy (NRT) to assist in this[5]. 40% of quit attempts
were made by cutting down first. A review of epidemiolog-
ical studies suggests that cutting down does not deter peo-
ple from cessation, but is associated with an increase
probability of trying to quit[6]. A survey of respondents to
an advertisement of people interested in cessation found
that 66% planned to stop by cutting down gradually,
while 13% planned to stop abruptly. In a second survey of
people who responded to an advertisement for those
planning to reduce smoking, 57% planned to reduce then
stop[7]. A survey of American daily smokers showed that
35% tried to stop gradually while 65% tried abruptly on
their last attempt[8]. Those who chose gradual cessation
were as motivated to stop and as confident of success as
those who used abrupt cessation. They had the same level
of dependence. A recently published random sample of
American smokers showed that nearly half of smokers
planning to quit would choose reduction over abrupt ces-
sation and two thirds of these were interested in using
medication to assist this[9]. In these smokers, there was
little interest in reduction as an end in itself, only as a
means to stop. Even among reducers not planning to stop
soon, cessation was the goal of half. People who want to
use gradual cessation to stop smoking soon have no NHS
treatment programmes to assist with their attempt. Thus
reduction as a means of stopping is likely to be popular,
as well as providing another option for smokers who have
tried and failed to stop previously.
Literature Review
Observational studies have reported that those using grad-
ual cessation were less likely to succeed than those using
abrupt methods[10,11]. One reason may be, that those
who chose gradual cessation as a means of quitting were
less motivated to stop[12]. We therefore sought to find
randomised trials. Based on Medline, Google Scholar,
Psych Abstract, Society for Research on Nicotine and
Tobacco abstract search, and a citation search plus contact
with key authors, we identified the following trials as the
only trials of abrupt and rapid reduction.
Marston & Mcfall randomised 65 students to one of four
behavioural treatments, of which two were gradual reduc-
tion and abrupt cessation, but did not report smoking ces-
sation rates[13]. In Gunther's trial, 55 smokers were
randomised to reduction over five weeks and 55 to abrupt
cessation after five weeks of behavioural support, fol-
lowed by a further seven weeks of support[14]. The trial
reports only relapse rates, but it is possible to calculate the
relative risk (RR), 95% confidence intervals (CI) for
unconfirmed undefined point prevalence abstinence at 12
months, which is 0.86 (0.44–1.68). Cinciripini ran-
domised 128 people into four groups, scheduled reduc-
tion, non-scheduled reduction, scheduled smoking prior
to quitting but no reduction, and normal smoking[15].
Baseline smoking rate was reduced by a third each week
over three weeks. All groups received identical post-cessa-
tion cognitive behavioural therapy. The confirmed pro-
longed abstinence rates at 12 months were 44%, 18%,
32%, and 22% respectively. The Mantel-Haenszel (M-H)
RR (95% CI) for reduction versus abrupt cessation is 1.14
(0.66–1.97). Flaxman randomised 64 participants to a 4 ×
2 factorial trial[16]. Of relevance, two of the arms were
gradual reduction and two abrupt cessation methods
(crossed with aversive smoking, no aversive smoking).
Post-cessation behavioural support was provided in each
arm. The M-H RR (95%CI) for reduction versus abrupt
cessation is 1.00 (0.47–2.13) for undefined unconfirmed
point prevalence at six months. Cummings randomised
1895 smokers to a 2 × 2 factorial trial of daily versus
unstructured self-help crossed with gradual versus abrupt
quitting plan[17]. For unvalidated prolonged abstinence
at six months, the M-H RR (95%CI) is 1.45 (0.87–2.42)
for gradual cessation, based on exclusion of the 19% lost
to follow up. The rates of loss were reported as 'fairly sim-
ilar' in each arm. Cinciripini has recently completed a 3-
arm study with participants randomised to cutting down
with scheduled smoking and nicotine patch, nicotine
patch pre-cessation treatment without reduction, or usual
post-cessation patch only[18]. The results are unpub-
lished, but preliminary data show improved cessation forPage 2 of 14
(page number not for citation purposes)
Trials 2009, 10:69 http://www.trialsjournal.com/content/10/1/69the reduction arm at four weeks but no evidence of differ-
ence between the arms in abstinence at six months. The
reduction arm had lower craving, fewer lapses, and less
negative affect (personal communication). Hughes is also
conducting a trial of reduction versus abrupt cessation
with no results as yet.
A second group of studies have led to a new use of NRT for
gradual cessation in a programme called Cut Down Then
Stop (CDTS). Critically, the CDTS trials enrolled smokers
who wanted to reduce their smoking but did not intend to
stop it in the next one or six months. They were ran-
domised to either NRT or placebo. The treatment pro-
gramme gives NRT over 6–9 months for reduction and for
a further three months post-cessation. The CDTS NRT pro-
gramme led to improvements in six month prolonged
abstinence over placebo (7% versus 3%), an RR (95%CI)
of 2.06 (1.34–3.15)[19]. Six months prolonged absti-
nence is a standard accepted for evidence of effectiveness
in smoking cessation[20]. Half of those who sustain absti-
nence for six months remain abstinent for their whole
lives[21]. These cessation rates are lower than those
achieved by the NHS smoking cessation services[22]. The
key point is that these were rates achieved in smokers who
said that they did not intend or want to stop imminently
(and who were on average highly addicted). It is possible
that the different intentions of smokers enrolled in CDTS
trials and those that use the abrupt quitting method
offered by the NHS explains the difference in prolonged
abstinence rates (7% versus 18% six months prolonged
abstinence). The CDTS studies demonstrate that reduc-
tion with NRT is more effective than without, but cannot
show whether reduction or abrupt cessation is more effec-
tive.
The positive effect of pre-quit NRT has also been discov-
ered in trials utilising the abrupt method of cessation, as
outlined in the recent Cochrane review, which summa-
rised trials that gave NRT patches for two weeks prior to
quit day in addition to after cessation. The RR (95% CI)
was 1.79 (1.17–2.72) compared with usual post-cessation
use only[23]. In all these pre-cessation trials, NRT patch
was used. Two studies used nicotine gum, with less
effect[24,25]. Shiffman and Ferguson conducted a meta-
analysis of four studies (three in the Cochrane review and
one other) that all used pre-cessation patch treatments (1
of the studies used pre-quit nicotine patch (PQNP) for 4
weeks and the remainder used PQNP for 2 weeks). PQNP
significantly increased the odds of abstinence both 6
weeks after quit date (Odds ratio (OR) = 1.96), and at 6
months (OR= 2.17)[26]. Participants were twice as likely
to quit if they used PQNP, when compared to participants
who started nicotine patch treatment on their quit day.
Additionally post hoc observations found that in 3 of the
4 studies (relevant data were not available for the fourth
study) participants treated with PQNP spontaneously
reduced the amount of cigarettes they smoked, and those
who reduced more of their own accord were more likely
to quit. This may be because these participants were more
responsive to treatment or could be further evidence that
reduction can increase the chances of success in smoking
cessation.
There are psychological principles that suggest that reduc-
tion might be more effective than abrupt cessation. One is
shaping, obtaining a target behaviour (not smoking for
the rest of one's life) by making successive approxima-
tions of the target behaviour (gradual cessation produces
progressively longer periods of abstinence). The second is
the cognitive psychology principle that completing a step
toward a goal (reducing cigarettes per day) increases self-
efficacy that increases the likelihood of completing the
goal (abstinence). The third is classical and operant con-
ditioning principles that decreasing the association of
environmental cues (conditioned or discriminative stim-
uli) and a behaviour weakens the behaviour (smoking
reduction typically uncouples cues from smoking). The
fourth is the psychopathology principle that lowering
drug intake reduces drug dependence increasing ability to
abstain completely.
There is evidence that gradual reduction should be much
more rapid than used in the CDTS trials. In one CDTS
trial, Haustein (currently unpublished) participants were
randomised in a 2 × 2 factorial design of NRT versus pla-
cebo and rapid versus slow reduction[27]. Despite enroll-
ing people who said they did not intend to stop smoking
in the next month, rapid reduction outperformed slow
reduction at the end of trial (12 months from baseline).
For confirmed 7-day point prevalence reduction, the M-H
RR (95%CI) is 1.01 (0.55–1.84), confirmed prolonged
abstinence it is 4.57 (1.00–20.93), and for confirmed pro-
longed reduction it is 2.69 (1.08–6.68). A pilot study ran-
domised 31 smokers ready to stop to reduce over two
weeks or three[28]. The quit rates were slightly higher in
the two week group and qualitative data indicated that
rapid reduction helped demarcate the boundary between
reducing and quitting.
Trial Objectives
Aim
To confirm or refute equivalence of two different behav-
ioural instructions in stopping smoking, namely reduc-
tion or abrupt cessation.
Objectives
1) To measure smoking abstinence at 4 week, 8 week and
6 month follow-up in both the abrupt and reduction
treatment arms.Page 3 of 14
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behavioural advice to reduce prior to quit day achieves its
effects.
Method
All methods outlined below are in compliance with the
Declaration of Helsinki as approved by the National
Research Ethics Service (08/H0408/213)
Why a non-inferiority trial?
Given reduction is so intuitive and appealing; it is likely to
attract smokers who would have used abrupt quitting had
reduction not been available. It is imperative to show that
such smokers would not be worse off if they opted for a
reduction programme and we propose to test this with a
non-inferiority trial. Non-inferiority trials can show supe-
riority but conventional superiority trials cannot show
non-inferiority[29]. We propose an unblinded pragmatic
trial large enough to show equivalence of the methods.
Inclusion criteria
Participants must meet all of the following inclusion cri-
teria to be eligible for enrolment into the trial:
1. males and females 18 years or older,
2. smokes at least 15 cigarettes or 12.5 grams of loose
tobacco daily as roll your own cigarettes, or blows 15
parts per million or above on exhaled carbon monox-
ide (CO) reading.
3. willing to stop smoking completely in two weeks
4. evidence of a personally signed and dated informed
consent document indicating that the subject has been
informed of all pertinent aspects of the study and con-
sents to participate and be randomised to either arm
5. be willing and able to comply with all study proce-
dures.
Exclusion criteria
Subjects presenting any of the following exclusion criteria
will not be included in the trial:
1. currently using other NRT, bupropion, nortriptyl-
ine, mecamylamine, reserpine, or varenicline, or
undergoing any treatment for tobacco dependence
(e.g. acupuncture),
2. unstable angina pectoris, myocardial infarction, or
cerebrovascular accident during the last 3 weeks,
3. severe cardiac arrhythmia
4. currently uncontrolled hyperthyroidism
5. active phaeocromocytoma
6. pregnancy, lactation or intended pregnancy
7. suspected alcohol or drug abuse
8. participation in other medicinal trials within the
last three months and during study participation,
9. previously had severe skin reactions to nicotine
patches or severe eczema or other skin diseases that
make patch use hazardous or undesirable.
10. a severe acute or chronic medical or psychiatric
condition or previously diagnosed clinically impor-
tant renal or hepatic disease, that may increase the risk
associated with study participation or may interfere
with the interpretation of study results and, in the
judgment of the investigator, would make the subject
inappropriate for entry into this study.
Withdrawal criteria
Trial Withdrawal: It is standard practice in smoking cessa-
tion trials to regard those who fail to attend for support
and treatment as having relapsed, which is based on some
evidence[20]. Therefore, failure to attend will not count as
withdrawal from the trial and the only withdrawals will be
those where a patient asks to be withdrawn. Such patients
will not be replaced and, unless s/he refuses permission,
data available up to that point will be used. Such with-
drawals are expected in fewer than 5% of participants.
This is standard procedure in smoking cessation studies.
Treatment withdrawal: One of our exclusion criteria is
previous adverse reactions to NRT; so given that most
smokers have used NRT recently, the established safety
profile of NRT and the evidence from trials of combina-
tion NRT, we do not expect any serious adverse events due
to the medication. Nevertheless, there will be a detailed
work instruction for the trial that will detail the weekly
assessment of side-effects, and the procedure for serious
adverse events (SAE) and suspected unexpected serious
adverse reactions (SUSARs). In the event of an SAE or
SUSAR that is judged either possibly, probably, or defi-
nitely related to NRT, the prescription for NRT will be
withdrawn and not re-instituted in that person.
Participant Recruitment
We will recruit participants through South Birmingham,
Solihull, Heart of Birmingham and Warwickshire and
Worcestershire Primary Care Trusts in several ways. We
will request that general practitioner's practices write to
patients on their practice lists recorded as smokers andPage 4 of 14
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smoking services write to people on their databases who
have tried to stop and failed. The letters sent out will ask
those patients who wish to take part in the trial to respond
to the research team. In our experience, 5–10% will
respond. Finally the trial treatment will also be offered to
people booking for treatment with stop smoking services.
Following telephone screening for preliminary eligibility,
potential participants will be booked in for an assessment
visit. Written informed consent will be obtained from par-
ticipants at the first assessment session before they have
been randomised to a treatment arm.
Participants in both treatment arms will be seen weekly
for 2 weeks prior to quit day, on quit day, and weekly for
4 weeks post-quit. A further follow-up visit will take place
8 weeks post quit-day and a final follow-up phone call at
6 months. Therefore all participants will be enrolled in the
trial for 6 months and 2 weeks.
It is not unusual for people to delay their quit day, once
committed, for a variety of reasons, e.g. death of a close
family member or friend. In this situation we will allow
participants to delay their quit attempt for a maximum of
2 weeks. They will be advised to carry on with their pre
quit NRT regime as prescribed and their actual quit date
appointment will be recorded as their visit 3 appoint-
ment. Extra visits in between week 2 and week 3 will be
recorded in the case record form and extra diaries and
NRT will be issued to the participants to cover their delay
period. Extra visit questionnaires will also be given to the
participant for completion. Participants wishing to delay
their quit day by >2 weeks will be classified as abandoning
this quit attempt, NRT will be ceased and the participant
will be advised to contact their local stop smoking service
when they are ready to set a new quit date. They will be
provided with the name and number of their local stop
smoking service.
Allocation to trial arms and treatments
Randomisation
Participants will be seen at an assessment session, similar
to that used by stop smoking services, where participants
will be randomised 1:1 to reduction or abrupt cessation in
the assessment session. We will use Stata to accomplish
stratified randomisation by therapist with blocking within
each stratum to ensure balance. The blocks will be ran-
domly ordered blocks of 2, 4, and 6. Each therapist will
open sealed numbered envelopes in turn after consent
and initial procedures to determine allocation to abrupt
cessation or rapid reduction.
Participants in the reduction arm will be offered a choice
of ways to reduce and asked to choose the method they
feel is right for them. Those without strong preferences
will be randomised to one of the three reduction meth-
ods. We will use Stata to accomplish stratified randomisa-
tion by therapist with blocking within each stratum to
ensure balance. The blocks will be randomly ordered
blocks of 3 and 6. Each therapist will open sealed num-
bered envelopes in turn after consent and initial proce-
dures to determine allocation to abrupt cessation or rapid
reduction.
It is quite likely that we will see couples, friends, or rela-
tives who want to quit together and attend clinic as a
group. In this situation they will be randomised together
so they go into the same arm and given the same study
number but made identifiable by adding an A or B to the
end of their number.
Behavioural intervention in the abrupt cessation (control) arm
Participants randomised to abrupt cessation will have a
brief discussion about smoking and about the nicotine
patch treatment. Participants will be informed that the
rationale of wearing the patch is to divorce the cigarette
smoking behaviour from its reward (the delivery of nico-
tine). The relatively high constant level of nicotine is
thought to blunt both the pharmacological cue to smoke
and the reward from smoking when it occurs. The instruc-
tion will therefore encourage the smoker not to reduce
consumption at all, even if they feel like smoking fewer
cigarettes, because this will work against the stated ration-
ale (not smoking will allow nicotine levels to fall to sub-
normal (for the participant) levels and create an urge to
smoke that will be rewarded by smoking). Patches will be
provided for use until the next visit and homework given
to identify critical cigarettes, which is the basis for the pre-
quit session discussion the next week, used in standard
behavioural support. This will be followed by five weekly
sessions on quit day and weekly thereafter, following the
typical 7-session UK withdrawal orientated therapy pro-
gramme[30]. Should a participant resume smoking dur-
ing this treatment, participants will be allowed to renew
their quit day following the new NHS standards. From
quit day onwards participants in this arm will get combi-
nation NRT, meaning patch plus top-up acute product of
their choice and be advised to use generous doses of NRT
because dose is related to outcome[31] and combination
treatment is more effective than patch alone[23]. Combi-
nation NRT is standard in our clinics and advised by the
National Institute for Health and Clinical Excellence for
dependent smokers[32]. Participants will be allowed to
choose the type of acute NRT they prefer. Participants will
be provided with a diary in weeks 1 and 2 to record the
number of cigarettes smoked per day, and whether
patches are being used, in week 3 this will be extended to
include the amount of acute NRT product used per day.Page 5 of 14
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The rapid reduction arm differs from the control arm only
in the advice given in the pre-quit period two weeks before
quit day. We will offer one of three reduction methods
and the participants who do not have a strong preference
for one or other method will be allocated at random to
one of the three methods. The therapist will have a second
set of sealed envelopes to accomplish this prepared as for
the main randomisation. The two methods that focus on
cigarettes per day will aim to reduce consumption to
<50% of baseline at the end of the first pre-quit week and
<25% by quit day.
The three methods are as follows:
a) Scheduled reduction (SR) method. In this method,
a median inter-cigarette interval is calculated and then
this altered so as to achieve the gradual reduction of
cigarettes per day. For example, if a person is typically
awake for 16 hours per day and smokes 16 cigarettes
per day, then the median inter-cigarette interval is 1
hour. To achieve a 50% reduction, the inter-cigarette
interval needs to increase to two hours. In this
method, a person must smoke every two hours
whether or not they want to do so. If they cannot
smoke, that cigarette is missed and the next opportu-
nity takes place two hours later. This method is poten-
tially difficult in a country with smoke-free laws and
for people with some types of jobs.
b) Hierarchical reduction. There are two variants: hier-
archical reduction- difficult (HR-D) and hierarchical
reduction- easy (HR-E). In this method, participants
classify their usual cigarettes as either habitual ciga-
rettes or particularly rewarding cigarettes. The HR-D
method aims to get participants to reduce smoking by
removing the difficult cigarettes first. The rationale is
that getting rid of the hardest ones is the most difficult
and if this can be accomplished well before total absti-
nence, this will enhance confidence and reduce the
chance of a slip. HR-E is similar to HR-D except that
participants seek to avoid smoking less rewarding or
easier cigarettes to forgo. The rationale is that this gives
participants early initial success and allows them con-
fidence to tackle more difficult cigarettes later. If allo-
cated to hierarchical reduction participants will be
able to choose whether they will forgo easier of more
difficult cigarettes first.
c) Smoke free periods (SFP). This method is different
to all other methods in that it does not focus on ciga-
rettes per day as the marker of reduction. In this
method, participants map out their typical day, mark-
ing the smoking periods of the day. In a country with
smoke free laws, smoking behaviour is concentrated
into smoking breaks, except perhaps when at home.
The SFP procedure will concentrate on reducing the
number of smoking periods over the reduction time.
In a smoking period, participants will be allowed to
smoke as much as they want, but they will not be
allowed to smoke outside the smoking period. The
rationale is that smokers typically report few urges to
smoke in places where smoking is forbidden, but find
that not smoking when it is allowed more difficult.
This method provides clear boundaries about when
smoking is and is not allowed, unlike all other meth-
ods that depend on reducing cigarettes per day except
perhaps scheduled reduction. It also focuses partici-
pants on what is being achieved- smoke free periods-
and not on what is being forgone- cigarettes not
smoked.
Each participant will complete a diary recording both the
target for that day and a report on whether the participant
met that target. In methods that focus on cigarettes per
day, participants will be asked to put aside the next day's
cigarettes into a separate pack to encourage adherence to
the target. Participants will be instructed to replace ciga-
rettes missed with a type of acute NRT (for example nico-
tine gum) and encouraged to use this sufficiently to avoid
smoking more cigarettes than quota or smoking in a
smoke-free period. Every evening, participants will record
cigarettes smoked, acute NRT used (and the remainder in
the packet), and note issues in a free text field. In a current
trial, we find most participants complete the diary relia-
bly.
Trial Medication
The trial takes place within the context of NHS smoking
cessation clinics, which provide behavioural support and
medication to assist smoking cessation. Around 70% of
smokers in these clinics use nicotine replacement therapy
(NRT) as their medication to assist quitting and this is the
only pharmacotherapy that will be available to partici-
pants in this trial. Current best practice is to use NRT in
combination, which has been endorsed by the Medicines
and Healthcare Regulatory Authority as good practice and
recommended by the National Institute for Health and
Clinical Excellence[32].
In this study, we propose using both nicotine patch and
an acute form of NRT in combination (See Table 1). We
will use Niquitin, Nicotinell, Wockhardt, and Nicorette
NRT products, including 24 hour patches, which are
licensed for 16 hour use also (there is no evidence that the
effectiveness of 16 hour patches or 24 hour patches is dif-
ferent[33]). These patches provide about 1 milligram
(mg) per hour of nicotine. Participants will be advised to
wear the patch 24 hours per day, but will be advised to
wear it only during day time should they experience sleepPage 6 of 14
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provide the same amount of nicotine delivery with similar
pharmacokinetics, the license dosing advice differs. Niq-
uitin CQ recommend the 21 mg patch for smokers who
smoke 10 or more cigarettes per day, while Nicotinell rec-
ommend the 30 cm2 (= 21 mg) patch for smokers of 20 or
more cigarettes per day. The evidence is that most smokers
who smoke 10 or more cigarettes per day get less nicotine
from their patch than they did from their ciga-
rettes[34,35]. We have therefore chosen a cut-off of 15 cig-
arettes per day. In addition, all participants will be offered
additional intra-nasal or oral nicotine replacement (gum,
microtabs, lozenges, or inhalator) with the choice of
delivery system left to personal preference. The dose of
these products used will vary, but participants will be
advised to take at least 1 mg of absorbed nicotine for each
cigarette forgone in the reduction phase because each cig-
arette delivers about 1.2 mg on average, though this is
highly variable[36]. A 2 mg oral product, for example
gum, delivers about 1 mg available systemically, and a 10
mg inhalator cartridge yields about 3 mg of nicotine that
is systemically available. In the cessation phase, partici-
pants in both arms will be given identical dosing instruc-
tions and advised to use at least 6 mg of absorbed nicotine
daily, which is the minimum dose associated with
improved outcomes[33].
Rationale of the pre-quit NRT in the abrupt and rapid 
reduction arms
By utilising pre-quit NRT in both arms we will ensure that
any effect is caused by the difference in reduction rather
than differences in nicotine intake. Smoking and using a
patch gives higher concentrations of nicotine than just
smoking, whereas smoking and using an acute form of
NRT does not[37]. It is thought that high levels of nicotine
dissociate the cigarette from its reward and this is respon-
sible for the effectiveness of nicotine pre-treatment, which
is not apparent when acute forms of NRT only are used.
Consequently, we have chosen a nicotine patch for both
arms. However, gradual reduction could undermine the
nicotine pre-treatment effect so we aim to keep nicotine
levels high using a patch during reduction and replacing
cigarettes with acute NRT.
Duration of medication use and discontinuation
The license for NRT allows continued use for up to 9
months, but patch use will be phased out using the step
down doses between 2 and 3 months after quit day. For
participants who are still lapsing but showing determina-
tion to stop smoking, the patch will be phased out more
slowly, providing no signs of overdose are evident. The
dose reduction regimes vary in the summary of product
characteristics and in any case the dose reduction is indi-
vidual, based upon confidence in reducing the patch dose
and occurrence of urges to smoke. Oral NRT is commonly
continued for several months in abstinent smokers [38-
41] and there are reasons to assume this is beneficial, and
again we will apply clinical judgement in deciding on
length of treatment of oral/intranasal NRT. The advice on
patch duration and oral NRT discontinuation will be the
same in both arms. At week +8 participants will be given
a month supply of NRT and advised to contact either their
general practitioner or local stop smoking service should
they need further support and/or prescriptions beyond
week +12.
Stopping rules/modification of medication regime
• Participants who have problems with insomnia or diffi-
culties with vivid dreams will use the patch for 16 hours
daily, not 24 hours
• Participants who have skin reactions to the patch that
are not controlled by switching preparations, emollient
and hydrocortisone cream will switch to acute NRT only.
• Participants who become pregnant may have their dose
adjusted in line with the National Institute for Health and
Clinical Excellence guidance and in accord with the
wishes of the participant.
• Participants who show symptoms of overdose will have
the dose reduced.
Table 1: Daily medication regimes
Rapid reduction Abrupt cessation
Pre-quit period -2 weeks to quit day 21 mg/24 hour patch,
1 mg of absorbed nicotine per cigarette forgone as 
a minimum from acute NRT.
21 mg/24 hour patch,
No acute NRT.
Quit day onward 21 mg/24 hour patch,
Minimum of 6 mg of absorbed nicotine from acute 
NRT. As much as needed to feel comfortable.
21 mg/24 hour patch,
Minimum of 6 mg of absorbed nicotine from acute 
NRT. As much as needed to feel comfortable.Page 7 of 14
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cease using NRT.
Evidence of safety of smoking whilst using NRT
The safety of using transdermal NRT while smoking was
investigated in a review by Fagerstrom & Hughes[37],
which is summarised in Table 2. In addition to this
review, we have recently systematically reviewed the Cut
Down to Stop (CDTS) studies mentioned in the literature
review[19]. As part of this, we performed a meta-analysis
of adverse events in people smoking and using NRT versus
those smoking and using placebo NRT. Overall, 1384 pre-
dominantly middle-aged smokers were treated with NRT
for 6 to 18 months, while 1383 were treated with placebo.
Four deaths occurred in those randomised to NRT and
four in those randomised to placebo; Odds ratio (OR)
1.00 95%CI 0.25–4.02. Serious adverse events occurred in
fewer than 8% of participants in both arms; OR 1.09
95%CI 0.79–1.50. In no cases were these were judged
likely to have been due to treatment. Discontinuation of
treatment due to adverse events was rare with 1.7% and
1.3% in the NRT and placebo groups; OR 1.27 95%CI
0.64–2.51. Nausea was selected as an index symptom to
indicate possible nicotine overdose. It was slightly and
significantly more common in the NRT group with 8.6%
versus 5.3% on placebo experiencing nausea; OR 1.69
95%CI 1.21–2.36.
Lifestyle advice
There is no special dietary or life-style advice that is
imposed by using NRT and the associated regimes for
using it proposed in the protocol. However, participants
using oral NRT will be advised to avoid acidic drinks 15
minutes prior to using oral NRT.
Concomitant Medication
All medications will be permitted for use concurrently,
except those that are proven to help smoking cessation
(bupropion, nortriptyline, mecamylamine, reserpine,
varenicline), or medications that are unlicensed and for
which no interaction data with NRT are available. No res-
cue therapies will be permitted in treatment, in accord-
ance with the National Institute for Health and Clinical
Excellence guidance on smoking cessation pharmacother-
apy[32]. The NRT itself is aimed at the relief of symptoms
of nicotine withdrawal. Should adverse skin reactions
occur with the use of the patch, advice will be given on the
use of over the counter emollients and 1% hydrocortisone
cream, as is standard. Data on all concomitant medication
will be recorded.
Trial Outcomes
Primary trial outcome
• Abstinence at four weeks, measured according to the
Russell standard[20,42]. The Russell standard allows a
two week grace period from quit day for slips[43].
Secondary trial outcomes
• Point prevalence at each follow up and prolonged
abstinence at 8 weeks and 6 months. Half of those sus-
taining abstinence for six months sustain it for life, the
goal of treatment[44,45].
Table 2: Summary of Fagerstrom & Hughes review of the safety of smoking and concomitant NRT use[37]
Study reviewed NRT treatment given Blood nicotine concentrations Safety conclusions
Foulds et al, 1992 16+ cigarettes per day (cpd) & 15 
milligram (mg) transdermal patch 
(TP) over 16 hrs
Baseline: 37 nanograms per 
millilitre (ng/ml), Placebo: 36 ng/ml, 
15 mg TP: 44 ng/ml.
Participants experienced almost no 
subjective toxic effects whilst 
wearing the patch
Pickworth, Bunker & Henningfield, 
1994
13+ cpd & 22 mg, 44 mg TP over 
24 hrs
Baseline: 30 ng/ml, Placebo: 19 ng/
ml,
22 mg TP: 39 ng/ml,
44 mg TP: 63 ng/ml.
No adverse subjective experiences 
were reported.
Mahmarian et al, 1997 8+ cpd & 14 mg TP over 24 hrs Baseline 16 ng/ml, 14 mg TP: 24 
ng/ml, 21 mg TP: 30 ng/ml.
Only adverse effects noted were 
nausea & vomiting in 2 patients.
Zevin, Jacob & Benowitz, 1998 Smoking ad libitum & 21 mg, 42 
mg, 63 mg patch over 8 hours
Placebo: 20 ng/ml, 63 mg TP: 60 
ng/ml.
No additional haemodynamic 
effects of TP on heart rate, blood 
pressure, noradrenaline, white 
blood cell count, fibrinogen, 
haematocrit, cortisol, or lipids. No 
adverse reactions.
Carpenter et al, 2000 11+ cpd & TP, gum or inhaler Lower than 22 mg TP: 54% 
increase, Higher than 22 mg TP: 
190% increase.
Number of cpd reduced by 43% 
and CO by 31%.Page 8 of 14
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will be measured after cessation. Urges to smoke are
an important proxy of return to smoking.
Other trial outcomes (non-efficacy)
• Exhaled carbon monoxide using a CO monitor is a
measure of smoke inhalation. We will compare smoke
exposure before quit day in both arms of the study.
• Cotinine levels, to show whether nicotine intake
rises from normal when smoking in both arms, as we
expect, and whether the rise in cotinine relates to the
success of treatment. We propose measuring cotinine
at baseline, week -1, quit day, and at week +1 on all
participants to examine whether reduction leads to
higher self-medication with nicotine. It could be that
reduction treatment gets people used to using high
doses of NRT and therefore some of the effect of treat-
ment could be explained by post-quitting NRT dose.
These data will also provide valuable evidence on nic-
otine consumption while smoking and using NRT.
• Participant rating of the reward from their cigarette
while smoking using the modified Cigarette Evalua-
tion Questionnaire (mCEQ)[46,47]. The mCEQ
measures satisfaction, taste, mood, cognitive, and sen-
sory sensations to smoking particular cigarettes. Twice
each week prior to quitting (to keep participant bur-
den reasonable), we will ask participants to rate satis-
faction from smoking from the first cigarette of the day
and one other key cigarette. We routinely ask partici-
pants to rate cigarette satisfaction in one specimen day
so as to anticipate danger periods for lapsing after ces-
sation. Typical rewarding cigarettes are after dinner.
Additionally, participants will be asked to rate a ciga-
rette smoked in a negative affect situation. It is possi-
ble that the mechanism of benefit may be the reward
from smoking, and this study will allow investigation
of this. We will also rate satisfaction from smoking
after cessation, should slips occur.
• Confidence in quitting is a predictor of abstinence
and might be modified by reduction and will be used
in mediation analysis. This will be measured by a sin-
gle question used in other trials that has been shown
to predict success. How high would you rate your
chances of giving up smoking for good at this attempt?
(Circle one response)
Extremely high
Very high
Quite high
Not very high
Low
Very low
• Smoking stereotypy is a measure of the degree to
which smoking is prompted by cues to smoke[48].
Perhaps reduction might work by disrupting stimulus
control and this scale could measure this. Two ques-
tions from this scale will be used to measure smoking
stereotypy because the other questions in the scale are
either forced to change or could not be assessed over a
short period.
There are no specific outcomes proposed when comparing
methods of reduction. This analysis will focus on the
above measures and is exploratory. See Table 3 for a
breakdown of which outcomes are to be measured at spe-
cific time-points [49].
In addition to the weekly clinic measures, participants will
complete a daily diary for the first three weeks of the trial
from week -2 to week +1. This will record whether or not
the patch is worn, the amount of acute NRT used, the
number of cigarettes smoked, and the two urge to smoke
questions from the Mood and Physical Symptoms Scale
(MPSS). Once a week, the diary will include the mCEQ,
with the other measure being taken in clinic.
Trial Statistics
Power calculation
We propose a non-inferiority trial following the Consoli-
dated Standards of Reporting Trials (CONSORT) state-
ment for such trials[29]. With a one-sided alpha of 0.05
we have 80% power to detect inferiority of 9.5% in the
quit rate at four weeks if we enrol 343 in each arm, assum-
ing 50% 4-week abstinence. Therefore the trial sample
size shall be N = 700. Analyses will be carried out on an
intention-to-treat basis, according to the Russell Standard,
where participants lost to follow up are assumed to be
smokers [20].
Arguably, differences of 5% at 4 weeks would be worth-
while detecting[50], but a trial would need to enrol 2500
participants for this, which would make it impractical and
unlikely to be funded. If the reduction produced absti-
nence rates not worse than 9.5% less at four weeks, this is
probably sufficient for stop smoking services to imple-
ment the programme.
Analysis
The analysis will compare the proportions stopping
smoking, calculating confidence intervals and relative
risks and confidence intervals. We will calculate differ-Page 9 of 14
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for baseline differences, as is standard using the
MPSS[51]. We will investigate possible mechanisms of
action (NRT dose, satisfaction from smoking, withdrawal,
self-efficacy) using mediation analysis within a regression
framework. Mediation analysis is outlined in more detail
by the RIPL research group at the Arizona State Univer-
sity[52].
In comparing methods of reduction, we have no specified
hypotheses. We will compare changes in confidence, ster-
eotypy, and urges to smoke calculating differences in
mean changes and confidence intervals for the difference.
We will compare the proportion abstinent using point
prevalence and prolonged abstinence as in the compari-
son between reduction and abrupt cessation. The primary
analysis of abrupt cessation versus reduction will not be
adjusted by method of reduction used.
Trial schedule
With two fulltime nurses who will also act as trial co-ordi-
nators and liaise with practices, and do follow ups, and
the support of a PhD student, we can see the 700 partici-
pants in 24 months (bearing in mind that clinical contacts
span 10 weeks).
Definition of end of trial
End of trial is defined as the final 6 month patient follow-
up measuring carbon monoxide level of the last partici-
pant undergoing the trial.
Safety Reporting
Assessment of safety
Potential participants' safety will be ensured by screening
for eligibility using a structured form completed by the
trial nurse. This will record evidence of eligibility and
exclusion criteria. In addition, the nurse will take a general
medical history to assess for other complicating diseases.
Any queries remaining as a result of this process will be
resolved by discussion between the trial nurse, chief inves-
tigator and the relevant physicians providing routine
medical care, usually the participant's general practi-
tioner. Such concerns are unusual but not rare. Typically,
they arise from a participant's hazy knowledge or under-
Table 3: Schedule of trial measures
Follow-up Trial measures
Baseline
(wk -2)
Smoking history, demographics, nicotine dependence using Fagerstrom Test for Nicotine Dependence 
(FTND)[49], urges and withdrawal (MPSS[51]), confidence in quitting, smoking stereotypy[48], cigarette 
satisfaction[47], future orientation questionnaire, exhaled carbon monoxide (CO), salivary cotinine, Give out 
diaries.
Pre-quit visit (wk -1) CO, cotinine, MPSS, confidence, smoking stereotypy, cigarette satisfaction, adverse events.
Collect diaries with daily smoking, NRT use, MPSS urge questions. Give out diaries.
Extra pre-quit visit
(wk -1a)
Only applicable if delays quit date by 1 week
CO, MPSS, confidence, smoking stereotypy, cigarette satisfaction, adverse events.
Collect diaries with daily smoking, NRT use. Give out diaries.
Extra pre-quit visit
(wk -1b)
Only applicable if delays quit date by 2 weeks
CO, MPSS, confidence, smoking stereotypy, cigarette satisfaction, adverse events.
Collect diaries with daily smoking, NRT use. Give out diaries.
Quit day
(wk 0)
CO, cotinine, MPSS, confidence, smoking stereotypy, cigarette satisfaction, adverse events.
Collect diaries with daily smoking, NRT use, MPSS urge questions. Give out diaries.
One week after quit day (wk +1) CO, cotinine, MPSS, confidence, cigarette satisfaction if lapsed, adverse events
Collect diaries with daily smoking, NRT use, MPSS urge questions
Post-quit visits (wks +2, +3, +4) Smoking in past week, CO, MPSS, confidence, cigarette satisfaction if lapsed, future orientation questionnaire at 
week 4, amount NRT used, adverse events
+8 wk visit Smoking in past 4 weeks, CO, MPSS, cigarette satisfaction if lapsed, confidence, amount NRT used, adverse 
events
6-month telephone call Smoking status over past 5 months, use of NRT. Those claiming 7-day abstinence will be invited to a validation 
visit for exhaled CO and to complete the future orientation questionnaire. Serious adverse events (SAEs)Page 10 of 14
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readily resolved. No blood or further medical testing will
be necessary to ensure safety.
NRT has been investigated in several hundred previous
clinical trials and is widely prescribed worldwide and sub-
ject to safety monitoring, and is replacing a product, nico-
tine, which the participants are already consuming and
will have consumed for many years in cigarettes. Thus,
there is every reason to expect that treatment in this trial
will be safe. Participants will be warned about the side-
effects of NRT and advised not to stop taking the medica-
tion without consulting with an NHS professional, prefer-
ably the trial team. To this end, all participants will be
given a credit card-sized card with the trial team's contact
details on that will allow participants to receive advice on
medication or to report perceived serious adverse effects
and receive advice on medication as required. Participants
will record the occurrence of side-effects of medication as
specified on the summary of product characteristics for
relevant NRT preparations, by completing a checklist. The
checklist will be given to the trial nurse and the nurse will
enquire about recorded adverse events, so as to determine
the severity of any adverse event and ensure that appropri-
ate advice is given for its management (such as rotating
the patch site or use of emollients for skin reactions).
Minor adverse reactions will be monitored and managed
in this way. For each known side effect listed in the sum-
mary of product characteristics, the trial nurse will have a
definition of clinical severity. For example, a mild skin site
reaction to the patch will be defined as burning sensation
that does not interfere with normal activities, redness or
swelling at the site of application, or mild blistering. Any
reaction beyond that will be classified as potentially mod-
erate or severe and will be reported to and discussed with
the principal investigator. A decision on stopping therapy
will then be made with the participant, attending clini-
cian, principal investigator, and other relevant parties as
appropriate. Nicotine has a short half life (2 hours),
meaning that the blood concentration will not build up
during the course of treatment so that new side-effects are
not expected after the first few weeks. In addition, with
reactions relating to local use, such as skin discomfort
from patches, or bad taste from oral use, either treatment
will have been switched or people become accustomed to
the side-effects after a short time of using the preparation.
At the last meeting (week 8 of the quit attempt), the par-
ticipant will be advised to phone the contact number to
report side-effects that occur after this. The advice given
will depend upon the severity of the reported reaction and
those with moderate reactions will be invited to an ad hoc
consultation.
Participants will also complete a schedule of nicotine
overdose symptoms at each visit. On completion of this
questionnaire, the schedule will be handed to the nurse
and thus any symptoms of overdose will be assessed. In
addition, based on her/his enquiry, the nurse will make
an assessment of whether the NRT dose is too high or not,
and then what action was taken, such as continue with
prescribed dose, or direct the participant to use a lower
dose, which will be recorded.
The summary of product characteristics for the relevant
NRT products contain no warnings about serious adverse
reactions except rare allergic reactions, such as
angioedema, and cardiac arrhythmias, occurring in less
than 1/1000 users. Thus we expect no or very few sus-
pected unexpected serious adverse reactions (SUSARs) in
this trial. The long history of use in and outside of trials
for NRT means that SUSARs are unlikely. On the reverse
of the trial card given the contact number for advice on
side-effect management, there will be instructions for the
reporting of serious adverse events. Through direct contact
from the participant or contact from their attending phy-
sician, we expect to become aware of serious adverse
events. If any member of the trial team becomes aware,
they will inform the PI within 24 hours. The principal
investigator will then assess the seriousness, causality,
expectedness and severity of the adverse effects. An imme-
diate decision will be made on the interim use of medica-
tion for that participant. If an event is judged severe, it will
be reported to the trial sponsor, who will report the event
to the Research Ethics Committee and Medicines and
Healthcare Regulatory Authority. Participants will be
asked weekly to report inter-current illnesses and the
response recorded. If any of these inter-current illnesses
contra-indicates NRT, this will be immediately reported to
the principal investigator and a decision made about con-
tinued use of the NRT product. The reporting procedures
and definitions are presented in Additional file 1.
Monitoring and audit
The progress of the trial will be monitored by quarterly
review of records. This will ensure that consent is being
obtained and the inclusion and exclusion criteria are
adhered to. The medication dispensed and the instruc-
tions for using it will also be assessed.
Data cleaning will take place by a series of logical checks
on the electronic data. (For example, a person cannot be
recorded as prolonged abstinent smoker at 6 months if
they were not in such a state at 8 weeks). Discrepant
records will be checked with the source documents and
the database amended if necessary.
The trial will be potentially subject to audit by the appro-
priate regulatory authorities and therefore participants
will be asked to consent to allow their records to be
viewed.Page 11 of 14
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The trial is being run as part of the portfolio of trials in the
Primary Care Clinical Research and Trials Unit
(PCCRTU), a National Institute for Health Research
(NIHR) recognised trials unit in Primary Care Clinical Sci-
ences at the University of Birmingham. The data manage-
ment will be run in accord with the standard operating
procedures, which are fully compliant with the Data Pro-
tection Act and International Conference on Harmonisa-
tion (ICH) Good Clinical Practice (GCP). The source
documents for the trial will be the case report forms which
will be stored in the trials unit in a locked cabinet in a
locked office in a locked department. The trial database
will be securely held and maintained by the PCCRTU. On
completion of the trial and data checking, the case report
forms will be transferred to Modern Records, a secure
archiving facility at the University of Birmingham, where
they will be held for 15 years and then destroyed. The
database will be anonymised and a secure compact disc
containing the link between identification number and
patient identifiable information will be stored in modern
records.
Data protection and confidentiality
Data will be kept in accordance with the Data Protection
Act and the trial registered with the Data Protection Act
website at the University of Birmingham. The standard
operating procedures of the trials unit will be followed,
which are designed to protect patient confidentiality.
Patient identifiable data will be shared only within the
clinical team on a need-to-know basis to provide clinical
care and ensure good and appropriate follow up. Patient
identifiable data will also be shared with the general prac-
titioner and approved auditors from the Research Ethics
Committee, NHS Research and Development, or the Med-
icines and Healthcare Regulatory Authority will also be
able to see patient identifiable information. Otherwise,
confidentiality will be maintained and no one outside the
trial team will have access to either the case report forms
or the database.
Ethics and Research Governance
The trial will be conducted in compliance with the princi-
ples of the Declaration of Helsinki (1996), the principles
of ICH-GCP and run in accord with EU Clinical Trials
Directive and all of the applicable regulatory require-
ments. The study protocol and other documentation have
been reviewed and approved by the National Research
Ethics Committee (08/H0408/213), the Medicines &
Healthcare Regulatory Authority, and local NHS Research
& Development offices. Any subsequent protocol amend-
ments will be submitted to the Research Ethics Commit-
tee for approval, and the other bodies if necessary. We will
comply with ICH-GCP Guidelines over the reporting of
adverse events, serious adverse events and suspected unex-
pected serious adverse reactions (SUSARS). In addition we
will provide the Research Ethics Committee with progress
reports as well as a copy of the Final Study Report.
Finance
The study will be funded by the British Heart Foundation
and service support costs will be claimed via the Compre-
hensive Clinical Research Network.
Publication
The trial results will be written up for submission to a peer
reviewed journal and the trial is registered with control-
led-trials.com. No data relating to individuals will be
identified in these publications.
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